Zenas BioPharma (ZBIO) Change in Accured Expenses (2023 - 2026)

Zenas BioPharma's Change in Accured Expenses history runs 4 years deep, the most recent figure standing at -$5.0 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 55.55% year-over-year to -$5.0 million; the TTM figure through Mar 2026 stood at $21.3 million (up 101.17% YoY), while the FY2025 annual figure was $15.1 million, down 31.78% from the prior year.
• Change in Accured Expenses was -$5.0 million for Q1 2026 at Zenas BioPharma, down from $9.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $16.3 million in Q2 2025 to a low of -$11.2 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $3.5 million across 4 years, with a median of $1.8 million in 2023.
• Biggest YoY gain for Change in Accured Expenses was 537.5% in 2025; the steepest drop was 3432.84% in 2025.
• A 4-year view of Change in Accured Expenses shows it stood at $3.2 million in 2023, then jumped by 267.0% to $11.9 million in 2024, then decreased by 17.4% to $9.8 million in 2025, then tumbled by 150.64% to -$5.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$5.0 million (Q1 2026), $9.8 million (Q4 2025), and $102000.0 (Q3 2025), per Business Quant data.